Validations Queue
106,328 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 5 of 21, 200 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
106,328
Reviewed
13
Filtered
4,152
page 5 / 21
Showing on page
200
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.62 | FDA ANDA075211: ACYCLOVIR (ACYCLOVIR) — AUROBINDO PHARMA USA | fda 2026-06-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA207825: DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (DOXYLAMINE SUCCINATE) — PHARMOBEDIENT | fda 2026-06-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA NDA022434: ARGATROBAN IN SODIUM CHLORIDE (ARGATROBAN) — CIPLA | fda 2026-06-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA203046: CODEINE SULFATE (CODEINE SULFATE) — LANNETT CO INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA074951: BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — STEVENS J | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA NDA211913: ABSORICA LD (ISOTRETINOIN) — SUN PHARM | fda 2026-06-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA088629: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — ANI PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA204021: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — NOVEL LABS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA202935: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — STRIDES PHARMA INTL | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA202097: FENTANYL-100 (FENTANYL) — KINDEVA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA NDA215960: UTEBZI (TEBIPENEM, PIVOXIL) — GLAXOSMITHKLINE LLC | fda 2026-06-17 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA202677: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — ALVOGEN | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA040860: CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE (ASPIRIN) — INGENUS PHARMS NJ | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA210175: OXYMORPHONE HYDROCHLORIDE (OXYMORPHONE HYDROCHLORIDE) — ASCENT PHARMS INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA219865: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — HETERO LABS LTD VI | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA217264: ESOMEPRAZOLE MAGNESIUM (ESOMEPRAZOLE MAGNESIUM) — MARKSANS PHARMA | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA078582: LEVETIRACETAM (LEVETIRACETAM) — STRIDES PHARMA | fda 2026-04-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA078956: LAMOTRIGINE (LAMOTRIGINE) — AUROBINDO PHARMA | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA NDA209500: CAPLYTA (LUMATEPERONE TOSYLATE) — INTRA-CELLULAR | fda 2026-04-24 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA BLA761055: DUPIXENT (DUPILUMAB) — REGENERON PHARMACEUTICALS | fda 2026-04-22 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.62 | FDA NDA217180: JAKAFI XR (RUXOLITINIB PHOSPHATE) — INCYTE CORPORATION | fda 2026-05-01 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.62 | FDA NDA021342: LEVO-T (LEVOTHYROXINE SODIUM) — CEDIPROF INC | fda 2026-05-04 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA213929: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — LEADING | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA NDA205422: REXULTI (BREXPIPRAZOLE) — OTSUKA | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA209125: ZOLEDRONIC ACID (ZOLEDRONIC ACID) — EUGIA PHARMA | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA062801: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA220465: ANDA220465 ((unspecified)) — SANDOZ INC | fda 2026-05-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA217482: CARBIDOPA AND LEVODOPA (CARBIDOPA) — RUBICON RESEARCH | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA NDA021078: MALARONE PEDIATRIC (ATOVAQUONE) — GLAXOSMITHKLINE | fda 2026-06-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA077494: RISPERIDONE (RISPERIDONE) — PH HEALTH | fda 2026-06-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA204937: BUPRENORPHINE (BUPRENORPHINE) — WATSON LABS TEVA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA040330: PERCOCET (ACETAMINOPHEN) — OZANTRI | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA075759: BUTORPHANOL TARTRATE (BUTORPHANOL TARTRATE) — RISING | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA040186: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — WATSON LABS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA076560: BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (ACETAMINOPHEN) — LGM PHARMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA212133: HYDROMORPHONE HYDROCHLORIDE (HYDROMORPHONE HYDROCHLORIDE) — ASCENT PHARMS INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA208593: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ABHAI LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA040736: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS NY | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA206718: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA218359: ACETAMINOPHEN AND IBUPROFEN (ACETAMINOPHEN) — AUROBINDO PHARMA LTD | fda 2026-06-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA040881: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — MIKART | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.62 | FDA ANDA089897: METHADONE HYDROCHLORIDE INTENSOL (METHADONE HYDROCHLORIDE) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.62 | FDA ANDA211484: LEVORPHANOL TARTRATE (LEVORPHANOL TARTRATE) — ACERTIS PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA022454: DATSCAN (IOFLUPANE I-123) — GE HLTHCARE INC | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA219973: PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM) — SHUANGCHENG | fda 2026-04-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA204687: VALSARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — SCIEGEN PHARMS | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA BLA125514: KEYTRUDA (PEMBROLIZUMAB) — MERCK SHARP DOHME | fda 2026-06-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA020310: NIZORAL ANTI-DANDRUFF (KETOCONAZOLE) — KRAMER | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA BLA761412: LANGLARA (INSULIN GLARGINE-ALDY) — SUNSHINE LAKE PHARMA CO LTD | fda 2026-04-29 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.61 | FDA ANDA204072: METHYLPREDNISOLONE (METHYLPREDNISOLONE) — TIANJIN TIANYAO | fda 2026-04-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA019901: ALTACE (RAMIPRIL) — KING PHARMS LLC | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA203103: PROPRANOLOL HYDROCHLORIDE (PROPRANOLOL HYDROCHLORIDE) — IPCA LABS LTD | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA215971: DEUTETRABENAZINE (DEUTETRABENAZINE) — AUROBINDO PHARMA LTD | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA BLA761285: WEZLANA (USTEKINUMAB-AUUB) — AMGEN INC | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA212068: VASOPRESSIN (VASOPRESSIN) — SANDOZ | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA211015: VERAPAMIL HYDROCHLORIDE (VERAPAMIL HYDROCHLORIDE) — SOMERSET THERAPS LLC | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA210329: TADALAFIL (TADALAFIL) — JUBILANT GENERICS | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA062800: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA219146: GADOBUTROL (GADOBUTROL) — ZENARA | fda 2026-06-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA210365: EPIDIOLEX (CANNABIDIOL) — JAZZ PHARMS RES | fda 2026-06-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA075468: CLONAZEPAM (CLONAZEPAM) — RUBICON RESEARCH | fda 2026-06-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA087393: METHADONE HYDROCHLORIDE (METHADONE HYDROCHLORIDE) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA211913: ABSORICA LD (ISOTRETINOIN) — SUN PHARM | fda 2026-06-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA040050: METHADOSE (METHADONE HYDROCHLORIDE) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA211748: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ALKEM LABS LTD | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA040800: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — ACTAVIS ELIZABETH | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA209036: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ABHAI LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA211690: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — SANALUZ | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA040834: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — PHARM ASSOC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA040860: CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE (ASPIRIN) — INGENUS PHARMS NJ | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA076604: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — ACTAVIS LABS FL INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA040881: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — MIKART | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA203794: NUCYNTA (TAPENTADOL HYDROCHLORIDE) — COLLEGIUM PHARM INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA040894: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — GENUS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA078769: OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — ACTAVIS ELIZABETH | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA209956: POMALIDOMIDE (POMALIDOMIDE) — TEVA PHARMS USA | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA205071: MILNACIPRAN HYDROCHLORIDE (MILNACIPRAN HYDROCHLORIDE) — BRECKENRIDGE | fda 2026-04-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA219293: DANZITEN (NILOTINIB TARTRATE) — AZURITY | fda 2026-04-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA205571: CARBAMAZEPINE (CARBAMAZEPINE) — ZYDUS PHARMS | fda 2026-04-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA210111: POMALIDOMIDE (POMALIDOMIDE) — BRECKENRIDGE | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA202420: CALCIUM ACETATE (CALCIUM ACETATE) — CHARTWELL MOLECULAR | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA216081: GADOBUTROL (GADOBUTROL) — HENGRUI PHARMA | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA218558: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — MICRO LABS | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA219531: SDAMLO (AMLODIPINE BESYLATE) — BRILLIAN PHARMA | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA063181: MINOCYCLINE HYDROCHLORIDE (MINOCYCLINE HYDROCHLORIDE) — WATSON LABS TEVA | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA BLA761381: OPDIVO QVANTIG (NIVOLUMAB) — BRISTOL-MYERS SQUIBB | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA212428: OXCARBAZEPINE (OXCARBAZEPINE) — CHARTWELL RX | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA211026: MACITENTAN (MACITENTAN) — SEASONS BIOTECH | fda 2026-05-19 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA216988: CLONAZEPAM (CLONAZEPAM) — RUBICON RESEARCH | fda 2026-05-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA220143: ANDA220143 ((unspecified)) — HETERO LABS LIMITED | fda 2026-05-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA081099: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — BARR | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA018569: FUROSEMIDE (FUROSEMIDE) — EPIC PHARMA LLC | fda 2026-06-02 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA021909: CHILDREN'S ALLEGRA HIVES (FEXOFENADINE HYDROCHLORIDE) — CHATTEM SANOFI | fda 2026-06-04 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA207429: SOTALOL HYDROCHLORIDE (SOTALOL HYDROCHLORIDE) — REGCON HOLDINGS | fda 2026-06-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA214470: HALOPERIDOL (HALOPERIDOL) — ALEMBIC | fda 2026-06-04 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA219287: GADOBUTROL (GADOBUTROL) — VIWIT PHARM | fda 2026-06-11 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA208795: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA214209: SUMATRIPTAN (SUMATRIPTAN) — CIPLA | fda 2026-06-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA202214: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — TRIS PHARMA INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA087508: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — GENUS LIFESCIENCES | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA219119: TAPENTADOL HYDROCHLORIDE (TAPENTADOL HYDROCHLORIDE) — NOVITIUM PHARMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA090118: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — SUN PHARM INDS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA040260: OXYCODONE AND ASPIRIN (ASPIRIN) — SUN PHARM INDUSTRIES | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA211499: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — ABHAI LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA203494: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — AUROBINDO PHARMA LTD | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA217596: LACOSAMIDE (LACOSAMIDE) — PROD DEVELOPMENT | fda 2026-06-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.61 | FDA ANDA208540: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ALVOGEN | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA022063: MYDAYIS (AMPHETAMINE ASPARTATE) — TAKEDA PHARMS USA | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA220313: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — AUROBINDO PHARMA | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA211489: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — AUROBINDO PHARMA | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA074712: LACTULOSE (LACTULOSE) — CUMBERLAND PHARMS | fda 2026-04-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA BLA761055: DUPIXENT (DUPILUMAB) — REGENERON PHARMACEUTICALS | fda 2026-04-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA218872: LENALIDOMIDE (LENALIDOMIDE) — ACCORD HLTHCARE | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA211132: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — INGENUS PHARMS LLC | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA022433: BRILINTA (TICAGRELOR) — ASTRAZENECA | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA BLA761070: FASENRA (BENRALIZUMAB) — ASTRAZENECA AB | fda 2026-05-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA219722: L-GLUTAMINE (L-GLUTAMINE) — ANNORA PHARMA | fda 2026-05-26 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA220041: TOPIRAMATE (TOPIRAMATE) — RICONPHARMA LLC | fda 2026-05-26 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA077747: OXCARBAZEPINE (OXCARBAZEPINE) — RUBICON RESEARCH | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA BLA761354: TOFIDENCE (TOCILIZUMAB-BAVI) — BIOGEN MA | fda 2026-05-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA215411: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) — INVENTIA HEALTHCARE LIMITED | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA021951: ABSORICA (ISOTRETINOIN) — SUN PHARM INDS INC | fda 2026-06-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA021131: ZYVOX (LINEZOLID) — PFIZER | fda 2026-06-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA200343: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — GENUS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA089990: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — STRIDES PHARMA INTL | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA204407: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — NOVEL LABS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA209021: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ASCENT PHARMS INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA209036: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ABHAI LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA087508: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — GENUS LIFESCIENCES | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA211690: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — SANALUZ | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA005010: DEMEROL (MEPERIDINE HYDROCHLORIDE) — QUAGEN | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA080448: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — SUN PHARM INDUSTRIES | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA203602: MORPHINE SULFATE (MORPHINE SULFATE) — NOVEL LABS INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA074278: LEVORPHANOL TARTRATE (LEVORPHANOL TARTRATE) — HIKMA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA201013: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AUROLIFE PHARMA LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA201448: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — SANKALP LIFECARE | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA090733: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — PH HEALTH | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA210793: NUPLAZID (PIMAVANSERIN TARTRATE) — ACADIA PHARMS INC | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA211559: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MACLEODS PHARMS LTD | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA214216: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE (EMTRICITABINE) — MACLEODS PHARMS LTD | fda 2026-04-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA214055: SELEXIPAG (SELEXIPAG) — RK PHARMA | fda 2026-04-16 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA216370: LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM) — ALEMBIC | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA208045: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — AUROBINDO PHARMA LTD | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA220787: ZAYNICH (CEFEPIME HYDROCHLORIDE) — WOCKHARDT BIO AG | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA207137: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA091440: LEVONORGESTREL AND ETHINYL ESTRADIOL (ETHINYL ESTRADIOL) — LUPIN LTD | fda 2026-06-16 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA207574: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — SANALUZ | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA206869: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS NY | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA206136: PIROXICAM (PIROXICAM) — STRIDES PHARMA | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA218740: CETRORELIX ACETATE (CETRORELIX ACETATE) — HUMANWELL | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA076780: ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA | fda 2026-04-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA018900: METRO I.V. IN PLASTIC CONTAINER (METRONIDAZOLE) — B BRAUN | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA211491: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — SUN PHARM | fda 2026-05-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA218093: FLECAINIDE ACETATE (FLECAINIDE ACETATE) — OMSAV PHARMA | fda 2026-04-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA075435: GABAPENTIN (GABAPENTIN) — TEVA PHARMS | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA219531: SDAMLO (AMLODIPINE BESYLATE) — BRILLIAN PHARMA | fda 2026-05-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA220717: ZOLPIDEM TARTRATE (ZOLPIDEM TARTRATE) — UMEDICA LABS PVT | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA078479: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — APOTEX | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA218088: REVEFENACIN (REVEFENACIN) — LUPIN INC. | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA008085: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — STRIDES PHARMA INTL | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA219319: GABAPENTIN (GABAPENTIN) — SENORES PHARMS | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA211747: OXCARBAZEPINE (OXCARBAZEPINE) — ZYDUS | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA075211: ACYCLOVIR (ACYCLOVIR) — AUROBINDO PHARMA USA | fda 2026-06-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA213703: CANGRELOR (CANGRELOR) — MSN | fda 2026-06-04 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA211000: MACITENTAN (MACITENTAN) — AMNEAL | fda 2026-06-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA203985: AFINITOR DISPERZ (EVEROLIMUS) — NOVARTIS PHARM | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA219165: PROPRANOLOL HYDROCHLORIDE (PROPRANOLOL HYDROCHLORIDE) — PAI HOLDINGS | fda 2026-06-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA204234: DOXYCYCLINE (DOXYCYCLINE) — LUPIN | fda 2026-06-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA209543: BOSUTINIB MONOHYDRATE (BOSUTINIB MONOHYDRATE) — ALEMBIC | fda 2026-06-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA207137: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA075351: BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — NOVITIUM PHARMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA205057: TAPENTADOL HYDROCHLORIDE (TAPENTADOL HYDROCHLORIDE) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA208708: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — RUBICON RESEARCH | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA208540: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ALVOGEN | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA218738: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — TEVA PHARMS INC | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA214956: GABAPENTIN (GABAPENTIN) — ASCENT PHARMS INC | fda 2026-04-24 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA205756: METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE) — RISING | fda 2026-04-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA208055: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — TORRENT | fda 2026-04-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA021977: VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — TAKEDA PHARMS USA | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA075388: BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE) — OXFORD PHARMS | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA205806: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — DR REDDYS LABS SA | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA220326: VILOXAZINE HYDROCHLORIDE (VILOXAZINE HYDROCHLORIDE) — APPCO PHARMA LLC | fda 2026-04-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA BLA761304: VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — ARGENX BV | fda 2026-05-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA019414: CARDIOGEN-82 (RUBIDIUM CHLORIDE RB-82) — BRACCO | fda 2026-05-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA203512: SPIRONOLACTONE (SPIRONOLACTONE) — ACCORD HLTHCARE | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA211035: VERAPAMIL HYDROCHLORIDE (VERAPAMIL HYDROCHLORIDE) — SOMERSET | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA218566: MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL) — CONCORD BIOTECH LTD | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA076584: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — RISING | fda 2026-06-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA213511: ELUXADOLINE (ELUXADOLINE) — AUROBINDO PHARMA | fda 2026-06-02 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA021980: FLUORESCITE (FLUORESCEIN SODIUM) — ALCON LABS INC | fda 2026-06-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA210985: METHYLPREDNISOLONE (METHYLPREDNISOLONE) — INGENUS PHARMS LLC | fda 2026-06-11 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA022434: ARGATROBAN IN SODIUM CHLORIDE (ARGATROBAN) — CIPLA | fda 2026-06-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA201194: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — VISTAPHARM LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA022207: MORPHINE SULFATE (MORPHINE SULFATE) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA BLA761324: EPKINLY (EPCORITAMAB-BYSP) — GENMAB US, INC. | fda 2026-06-17 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA040355: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — STRIDES PHARMA INTL | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA202214: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — TRIS PHARMA INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA205057: TAPENTADOL HYDROCHLORIDE (TAPENTADOL HYDROCHLORIDE) — HIKMA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA217449: BALOXAVIR MARBOXIL (BALOXAVIR MARBOXIL) — NORWICH | fda 2026-06-17 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA040838: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — PHARM ASSOC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% |